KORU Medical Systems, Inc.

KORU Medical Systems, Inc. is currently overvalued with significant negative financial metrics, including a Price to Book Value of 9.34 and an EV to EBITDA of -29.78, indicating financial distress compared to healthier peers, despite a strong 1-year return of 51.31%.

As of August 4, 2020, KORU Medical Systems, Inc. is considered overvalued with a risky valuation grade, reflected by a high price-to-book ratio of 9.34, a negative EV to EBITDA of -29.78, and a troubling ROCE of -69.30%, despite recent stock performance exceeding the S&P 500.

As of June 10, 2025, the trend is mildly bullish, supported by weekly and monthly MACD and KST indicators, although daily moving averages remain mildly bearish, indicating mixed signals and caution in the overall bullish sentiment.

As of March 2022, the management team of KORU Medical Systems, Inc. includes R. John Fletcher (Independent Chairman), Joseph Manko (Lead Independent Director), Daniel Goldberger, Robert Allen, David Anderson, and James Beck (all Independent Directors), responsible for the company's strategic direction and governance.

KORU Medical Systems, Inc. develops and manufactures portable medical devices for the ambulatory infusion market, with recent net sales of $10 million and a market cap of $161.07 million. The company reported a net profit loss of $1 million for the most recent quarter.

As of Jun 18, KORU Medical Systems, Inc. has a market capitalization of 161.07 million and reported net sales of 35.09 million with a net profit of -5.30 million over the last four quarters.